Clinical Trials
Zavzpret safe, provides acute and sustained relief for migraine
BOSTON — Intranasal Zavzpret was safe and effective for acute treatment of migraine, providing pain relief as early as 15 minutes after administration, according to a presenter at the American Academy of Neurology annual meeting.
FDA approves Lumryz for cataplexy, excessive daytime sleepiness in adults with narcolepsy
The FDA has approved Lumryz, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
FDA approves Qalsody for SOD-1 ALS
The FDA has approved Qalsody, an antisense oligonucleotide, to treat individuals with ALS associated with a mutation in the superoxide dismutase 1 gene.
FDA grants fast track designation to exon-skipping Duchenne muscular dystrophy therapy
The FDA has granted fast track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping, Avidity Biosciences announced in a press release.
Targeted drug demonstrates safety, potential to stop cancer growth in early trials
A targeted cancer drug developed by researchers at Norwegian University of Science and Technology and spin-off company APIM Therapeutics has demonstrated positive findings in phase 1 trials, according to a paper published in Oncogene.
Topline results: Donanemab superior to aducanumab in early symptomatic Alzheimer’s disease
BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the American Academy of Neurology annual meeting.
Cancer center’s mural promotes representation in clinical trials, ‘could really save lives’
Vania Soto sometimes has to clarify the story she is telling through her mural at Guadalupe Centers Middle School in Kansas City, Missouri.
Tolebrutinib associated with long-term safety, efficacy in relapsing-remitting MS
BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.
Lumevoq demonstrates sustained improvement of BCVA up to 5 years in LHON
BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.
Dermatological clinical trials lack racial, ethnic diversity
Individuals with skin of color were underrepresented in dermatological clinical trials, with those who were Black or African American being most underrepresented regardless of disease prevalence, according to a study.